Press Releases

Immunexpress.com

European and U.S. Patent Allowances Strengthen Immunexpress’ Leading Position in Host-Response Sepsis Diagnostics

Patent Allowances Relate to SeptiCyte™ Technology Using Biomarkers These allowances further reinforce the claims of the core family of patents that support the Company’s gene expression technology in the detection of host response to sepsis SEATTLE, Sept. 24, 2018 – Immunexpress, Inc., today announced the receipt of ‘Notices of Allowance’...
Immunexpress.com

Immunexpress Receives Notice of U.S. Patent Allowance for SeptiCyte™ Technology to Quantify Biomarkers

The allowance complements the Company's growing patent portfolio of gene technology in the detection of host response to sepsis SEATTLE, July 26, 2018 /PRNewswire/ -- Immunexpress, Inc. today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for U.S. Patent Application No. 15/160749, "Validating biomarker...
Immunexpress.com

Immunexpress Continues Executive Team Expansion with Addition of Fayyaz Memon as VP of Regulatory Affairs & Quality

SEATTLE, July 10, 2018 /PRNewswire/ -- Immunexpress, Inc. today announced that Fayyaz Memon, MBA, MS, has joined the company's Executive Team as Vice President of Regulatory Affairs and Quality. "Mr. Memon arrives at a key time for the Company as we continue to fortify our leadership team with accomplished individuals well-versed in the life sciences...
Immunexpress.com

Immunexpress Strengthens Board of Directors with Key Appointments

Accomplished Industry Leaders Join Recently Appointed CEO, Dr. Rolland Carlson, to Expand on the Comprehensive Experience of the Board SEATTLE, May 15, 2018 /PRNewswire/ -- Immunexpress, Inc. today announced the appointment of three new members to its Board of Directors. Rolland Carlson, PhD, Tanja Dowe and Katleen Verleysen, PhD, have joined the company's board, while Bea Arnold, PhD, has stepped...
Immunexpress.com

SeptiCyte™ LAB Differentiates Sepsis from SIRS in the ICU

Design and results of clinical trials that led to FDA clearance of SeptiCyte™ LAB published in the American Journal of Respiratory and Clinical Care Medicine SEATTLE, May 9, 2018 /PRNewswire/ -- Immunexpress, Inc. today announced the publication in the American Journal of Respiratory and Clinical Care Medicine of the design and results of clinical trials...
Immunexpress.com

Immunexpress Appoints Rolland Carlson, Ph.D., as Chief Executive Officer

Industry veteran brings a successful track record fundraising and launching commercial products Appointment strengthens the leadership team and positions the company for its targeted commercial launch   SEATTLE, April 10, 2018 – Immunexpress, Inc. today announced the appointment of Rolland D. Carlson, Ph.D., as chief executive officer, effective April 9,...
Immunexpress.com

Biocartis & Immunexpress Sign Partnership for a Sepsis Host Immune Response Test on the Idylla™ platform

Mechelen (Belgium)/Seattle (United States), 24 January 2018 – Biocartis Group NV (‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART) and Immunexpress Pty Ltd (‘Immunexpress’), a host response molecular diagnostic company, committed to improving clinical and economic outcomes for suspected sepsis patients, today announce that they have entered into a...
Immunexpress.com

Four-Biomarker Signature Differentiates Viral and Non-Viral Causes of Systemic Inflammation

Results from an investigation of over 40 datasets published in Scientific Reports SEATTLE, June 6, 2017 /PRNewswire/ -- Immunexpress, Inc., a molecular diagnostic company with the first FDA cleared host response assay for suspected sepsis patients, today announced the publication, in Scientific Reports, of data demonstrating the ability of a four-biomarker...
Immunexpress.com

Revolutionary Diagnostic SeptiCyte™ LAB Cleared By FDA for Suspected Sepsis Patients

SEATTLE, Feb. 22, 2017 – Immunexpress, Inc., a molecular diagnostic company committed to improving outcomes for suspected sepsis patients and healthcare providers, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the use of SeptiCyte™ LAB as an aid in differentiating infection-positive (sepsis)...
Immunexpress.com

SeptiCyte™ LAB Differentiates Sepsis from Infection-Negative Systemic Inflammation in Critically Ill Children

Results of a Pilot Study of SeptiCyte™ LAB in the Pediatric Setting Published in Critical Care Medicine SEATTLE, Sept. 22, 2016 /PRNewswire/ -- Immunexpress, Inc., a molecular diagnostic company committed to improving outcomes for suspected sepsis patients and patients at risk of sepsis, announced today the publication, in Critical Care Medicine,...
Immunexpress.com

SeptiCyte™ LAB Outperforms Other Parameters for Distinguishing Sepsis in Data Presented at the American Thoracic Society International Conference

SEATTLE, May 18, 2016 -- Immunexpress, Inc., a molecular diagnostic company committed to improving outcomes for suspected sepsis patients, today announced that SeptiCyte™ LAB outperformed other clinical and laboratory parameters at distinguishing infection-negative systemic inflammation response syndrome (SIRS) from infection-positive systemic inflammation (sepsis). The data from the VENUS study were presented by...
Immunexpress.com

Immunexpress Announces Presentation at the American Thoracic Society International Conference on the Validation of SeptiCyte™ LAB

SEATTLE, May 11, 2016 -- Immunexpress, Inc., a molecular diagnostic company committed to improving outcomes for suspected sepsis patients, today announced that data from the VENUS trial validating SeptiCyte™ Lab as a novel immune response assay to distinguish between SIRS and sepsis in critically ill patients will be presented at the...